---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: CDK4/6 inhibitors after progression on a CDK4/6 inhibitor"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: CDK4/6 inhibitors after progression on a CDK4/6 inhibitor. Topics: Guideline recommendation: NCCN, another CDK4/6 inhibitor after progression; Guideline recommendation: ABC8, CDK4/6 inhibition beyond progression; Guideline recommendation: ASCO 2021, fulvestrant plus a CDK4/6 inhibitor; Comparator regulatory information: abemaciclib; 8 further topics. 12 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/cdk4-6-inhibitors-after-progression-on-a-cdk4-6-inhibitor"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: CDK4/6 inhibitors after progression on a CDK4/6 inhibitor

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 CDK4/6 Inhibitors After Progression on a CDK4/6 Inhibitor

<a id="topic-2.2.2.1.3-1"></a>

### Guideline recommendation: NCCN, another CDK4/6 inhibitor after progression

> “The panel notes that if there is disease progression while on CDK4/6 inhibitor therapy, there are limited data to support an additional line of therapy with another CDK4/6 inhibitor-containing regimen (Figure 4).”
> “The panel recommends treatment with fulvestrant + CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib), if CDK4/6 inhibitor was not previously used (category 1).”
> “postMONARCH and MAINTAIN have not shown a OS benefit.”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.3-2"></a>

### Guideline recommendation: ABC8, CDK4/6 inhibition beyond progression

> “In view of the modest absolute benefit, the suboptimal control arm, and the availability of multiple biomarker-driven options in the post-CDK4/6i setting, the panel considers continued CDK4/6i beyond progression a less preferred strategy, reserving it for patients without access to other targeted therapies and in whom prior CDK4/6i benefit exceeded 12 months; when used, both the CDK4/6i and the endocrine agent should be changed.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.1.3-3"></a>

### Guideline recommendation: ASCO 2021, fulvestrant plus a CDK4/6 inhibitor

> “Fulvestrant and a CDK4/6 inhibitor should be offered to patients with progressive disease during treatment with AIs (or who develop a recurrence within 1 year of adjuvant AI therapy) with or without one line of prior chemotherapy for metastatic disease, or as first-line therapy. Treatment should be limited to those without prior exposure to CDK4/6 inhibitors in the metastatic setting (type: evidence-based, benefits outweigh harms; evidence quality: high; strength of recommendation: strong).”

Source: [Burstein et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8659999/)

<a id="topic-2.2.2.1.3-4"></a>

### Comparator regulatory information: abemaciclib

> “in combination with fulvestrant for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.”

Source: [Verzenio prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208716s022lbl.pdf)

<a id="topic-2.2.2.1.3-5"></a>

### Abemaciclib plus fulvestrant, postMONARCH: progression-free survival

> “At the primary analysis (258 events), the hazard ratio (HR) was 0.73 (95% CI, 0.57 to 0.95; nominal P = .017), with median PFS 6.0 (95% CI, 5.6 to 8.6) versus 5.3 (95% CI, 3.7 to 5.6) months and 6-month PFS rates of 50% and 37% in the abemaciclib + fulvestrant and placebo + fulvestrant arms, respectively. These results were supported by BICR-assessed PFS (HR, 0.55 [95% CI, 0.39 to 0.77]; nominal P < .001).”
> “Among patients with measurable disease, investigator-assessed ORR was improved with abemaciclib + fulvestrant versus placebo + fulvestrant (17% v 7%; nominal P = .015).”

Source: [Kalinsky et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11936477/)

<a id="topic-2.2.2.1.3-6"></a>

### Abemaciclib plus fulvestrant, postMONARCH: overall survival

> “Median OS was 32.1 months with abemaciclib plus fulvestrant versus 24.6 months with placebo plus fulvestrant (HR 0.80, 95% CI 0.60-1.06, P = 0.11, boundary for significance not reached).”
> “Updated PFS was consistent with the primary analysis (HR 0.78, 95% CI 0.62-0.99, nominal P = 0.039).”

Source: [Kalinsky et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42926108/)

<a id="topic-2.2.2.1.3-7"></a>

### Ribociclib with switched endocrine therapy, MAINTAIN

> “Of the 119 randomly assigned participants, 103 (86.5%) previously received palbociclib and 14 participants received ribociclib (11.7%). There was a statistically significant PFS improvement for patients randomly assigned to switched ET plus ribociclib (median, 5.29 months; 95% CI, 3.02 to 8.12 months) versus switched ET plus placebo (median, 2.76 months; 95% CI, 2.66 to 3.25 months) HR, 0.57 (95% CI, 0.39 to 0.85); P = .006.”
> “At 6 and 12 months, the PFS rate was 41.2% and 24.6% with ribociclib, respectively, compared with 23.9% and 7.4% with placebo.”

Source: [Kalinsky et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37207300/)

<a id="topic-2.2.2.1.3-8"></a>

### Palbociclib continued with fulvestrant, PACE

> “Palbociclib was the most common previous CDK4/6i (90.9%). The median PFS was 4.8 months on F and 4.6 months on F + P (hazard ratio [HR], 1.11 [90% CI, 0.79 to 1.55]; P = .62).”
> “The addition of palbociclib to fulvestrant did not improve PFS versus fulvestrant alone among patients with hormone receptor-positive/HER2- MBC whose disease had progressed on a previous CDK4/6i plus AI.”

Source: [Mayer et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38513188/)

<a id="topic-2.2.2.1.3-9"></a>

### Imlunestrant plus abemaciclib, EMBER-3: combination arm

> “Among 426 patients in the comparison of imlunestrant–abemaciclib with imlunestrant, the median progression-free survival was 9.4 months and 5.5 months, respectively (hazard ratio, 0.57; 95% CI, 0.44 to 0.73; P<0.001).”
> “However, most patients (65%) in the imlunestrant–abemaciclib group in our trial had received a CDK4/6 inhibitor previously, and the treatment effect of imlunestrant–abemaciclib (hazard ratio for progression or death, 0.51) in these patients was consistent with that in the overall population, and the median progression-free survival was 9.1 months.”

Source: [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.1.3-10"></a>

### Imlunestrant plus abemaciclib, EMBER-3: ESR1-mutated subgroup in the approval

> “In an exploratory subgroup analysis in 159 patients with ESR1 mutated tumors for the combination, the PFS HR estimate was 0.53 (95% CI: 0.35, 0.80). Median PFS in patients with ESR1 mutated tumors was 11.1 months (95% CI: 7.4, 13.7) in the imlunestrant and abemaciclib arm and 5.5 months (95% CI: 3.8, 7.2) in the imlunestrant alone arm.”
> “At the time of interim analysis, OS data was immature with 35% of deaths in patients with ESR1 mutated tumors.”

Source: [FDA imlunestrant and abemaciclib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-combination-abemaciclib-er-positive-her2-negative-esr1-mutated-advanced-or)

<a id="topic-2.2.2.1.3-11"></a>

### Imlunestrant plus abemaciclib: NCCN subgroup with prior CDK4/6 inhibitor

> “In those previously treated with a CDK4/6 inhibitor with ESR1-mutated tumors, the median PFS with doublet (n=53) versus the single agent (n=72) was 11.1 versus 5.4 months, respectively (HR, 0.44; 95% CI, 0.28–0.70). The grade ≥3 toxicities were higher with the combination therapy, seen in 49% versus 17%.”
> “Although the combination showed a PFS benefit in the overall population, it is noteworthy that the trial design did not include a comparison with the established combination of fulvestrant + abemaciclib.”

Source: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

<a id="topic-2.2.2.1.3-12"></a>

### Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib: indirect treatment comparison

> “Though not powered for formal hypothesis testing, PFS favored imlunestrant + abemaciclib versus fulvestrant + abemaciclib across all three ITC methods. Hazard ratios (95% confidence intervals) for Bucher, MAIC, and PSM were 0.77 (0.58-1.04), 0.77 (0.55-1.06), and 0.83 (0.56-1.22), respectively.”

Source: [Jhaveri et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12972957/)

Additional sources: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
